JAK Inhibitors for Lung Cancer - A Pipeline Analysis Report
- Published: Jun 2018
- Pages: 44
- SKU: IRTNTR22967
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for JAK inhibitors for lung cancer including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Overview of the drug development pipeline for JAK inhibitors for lung cancer
Lung cancer leads to the cells of the lungs to grow uncontrollably and spread to lymph nodes and various other organs of the body. Lung cancers can be classified into two main categories including small cell lung cancer and NSCLC. However, both these types of lung cancer can grow differently and are treated differently as well. The members of the signal transducer and activator of transcription family of transcription factors are potential targets for the prevention and treatment of various cancers including lung cancer. Humans have about four Janus kinase (JAK) family members including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK1 has been believed to have a crucial role in both oncologic and autoimmune diseases. It also forms heterodimeric complexes with JAK2, JAK3, and TYK2 and acts as an inflammatory signaling and immunomodulatory kinase. According to the CDC, lung cancer is one of the leading causes of cancer mortality and the second most diagnosed cancer in both men and women in the US. Technavio’s market research analysts suggest, the increasing number of instances of lung cancer is expected to promote the drug development for JAK inhibitors for lung cancer in the upcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for lung cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development molecules for the lung cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Dizal Pharmaceutical
- Incyte
- Pfizer
Therapeutic assessment of the drug development pipeline for JAK inhibitors for lung cancer by route of administration
- Oral
- Unknown
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for JAK inhibitors for lung cancer by therapy
- Monotherapy + combination therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for JAK inhibitors for lung cancer are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for JAK inhibitors for lung cancer?
- What are the companies that are currently involved in the development of drug development for JAK inhibitors for lung cancer?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
- US
- Europe
- China
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases

DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts

REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
